Notizie Newsletter

12 Novembre 2019

FDA approves first therapy to treat patients with rare blood disorder

November 8, 2019 - Today the U.S. Food and Drug Administration granted approval to luspatercept–aamt for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. “When patients ...
Leggi tutto

8 Novembre 2019

ASCO Congratulates Stephen M. Hahn, MD, FASTRO, on Nomination to Serve as FDA Commissioner

November 1, 2019 - Based on strong findings for efficacy and safety, as well as FDA approvals, the Society for Immunotherapy of Cancer (SITC) has issued the first guidelines for the use of immunotherapy agents in patients with recurrent or metastatic (RM) head and neck squamous ...
Leggi tutto

8 Novembre 2019

Statement on the agency’s efforts to protect patients through postmarket drug safety surveillance practices

November 6, 2019 - Public health and safety is the highest priority at the U.S. Food and Drug Administration. We maintain a robust practice of postmarket surveillance and risk evaluation programs to identify new adverse events that did not appear during the product development ...
Leggi tutto

8 Novembre 2019

Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018

We previously reported that quality of life (QoL) is not included among trial endpoints and QoL results are underreported in a significant proportion of phase III oncology trials. Here we describe QoL adoption, reporting and methodology of QoL analysis in lung cancer trials. ...
Leggi tutto

8 Novembre 2019

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

There have been substantial changes in the management of men with metastatic hormone-sensitive prostate cancer (mHSPC) over the past 5 yr, with upfront combination therapies replacing androgen-deprivation therapy (ADT) alone. A range of therapies have entered the space ...
Leggi tutto

8 Novembre 2019

Final results of a prospective study of scalp cooling in preventing chemotherapy-induced alopecia

Alopecia is a distressing effect of cancer treatments. Our study examined efficacy and safety of scalp cooling to prevent chemotherapy-induced alopecia. Early breast cancer patients candidate to anthracycline and/or taxane were eligible. Dean's alopecia scale was used to ...
Leggi tutto

8 Novembre 2019

4 novembre 2019 – Chiusura Managed Entry Agreements (MEA) Registro Brentuximab vedotin (Takeda)

8 Novembre 2019

5 novembre 2019 – Vitamina D – chiarimenti sulla Nota 96

8 Novembre 2019

7 novembre 2019 – Domenico Mantoan nuovo Presidente del CdA dell’Agenzia Italiana del Farmaco

8 Novembre 2019

8 novembre 2019 – Attivazione web e pubblicazione schede di monitoraggio – Registro Brentuximab vedotin (Takeda)

LAVORIAMO CON

News

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

MIASTENIA GRAVIS, 15MILA PERSONE COLPITE IN ITALIA. “UN’INSTALLAZIONE IMMERSIVA PER COMPRENDERE LA VITA DEI PAZIENTI E AUMENTARE LA CONSAPEVOLEZZA”

MELANOMA, IN ITALIA POSSONO ESSERE “EREDITARI” 2.600 CASI L’ANNO. IMI: “LA PREVENZIONE SIA ANCHE ESAMI GENETICI E SORVEGLIANZA CUTANEA”

FDA approves first therapy to treat patients with rare blood disorder

ASCO Congratulates Stephen M. Hahn, MD, FASTRO, on Nomination to Serve as FDA Commissioner

Statement on the agency’s efforts to protect patients through postmarket drug safety surveillance practices

Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018

Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis

Final results of a prospective study of scalp cooling in preventing chemotherapy-induced alopecia

4 novembre 2019 – Chiusura Managed Entry Agreements (MEA) Registro Brentuximab vedotin (Takeda)

5 novembre 2019 – Vitamina D – chiarimenti sulla Nota 96

7 novembre 2019 – Domenico Mantoan nuovo Presidente del CdA dell’Agenzia Italiana del Farmaco

8 novembre 2019 – Attivazione web e pubblicazione schede di monitoraggio – Registro Brentuximab vedotin (Takeda)